



# VIJAYA DIAGNOSTIC CENTRE

# VIJAYA DIAGNOSTIC CENTRE LIMITED

Our Company was incorporated as Vijaya Diagnostic Centre Private Limited on June 5, 2002 with a certificate of incorporation issued by the Registrar of Companies, Andhra Pradesh at Hyderabad. Subsequently, our Company was converted from a private limited company to a public limited company, pursuant to a special resolution passed by our Shareholders at the EGM held on March 22, 2021 and the name of our Company was changed to Vijaya Diagnostic Centre Limited on March 26, 2021, and a fresh certificate of incorporation consequent on change of name was granted by the Registrar of Companies, Telangana at Hyderabad. For further details, see “History and Certain Corporate Matters” on page 130 of the Red Herring Prospectus dated August 24, 2021 (“RHP”).

**Registered Office:** 3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad-500 029, Telangana, India; **Tel:** +91 40 2342 0411; **Corporate Office:** #6-3-883/F, Ground Floor of Family Planning Association of India, Panjagutta, Hyderabad-500 082, India. **Website:** www.vijayadiagnostic.com; **Contact Person:** V. Sri Lakshmi, Company Secretary and Compliance Officer; **E-mail:** ir@vijayadiagnostic.in; **Corporate Identity Number:** U85195TG2002PLC039075

## OUR PROMOTER: DR. S. SURENDRANATH REDDY

INITIAL PUBLIC OFFER OF EQUITY SHARES OF FACE VALUE OF ₹1 EACH (“EQUITY SHARES”) OF VIJAYA DIAGNOSTIC CENTRE LIMITED (“COMPANY” OR “ISSUER”) FOR CASH AT A PRICE OF ₹[●] PER EQUITY SHARE (“OFFER PRICE”), THROUGH AN OFFER FOR SALE OF UP TO 35,688,064 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION (“OFFER”) BY THE SELLING SHAREHOLDERS, COMPRISING OF UP TO 5,098,296 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY DR. S. SURENDRANATH REDDY (“PROMOTER SELLING SHAREHOLDER”), UP TO 29,487,290 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY KARAKORAM LIMITED AND OF UP TO 1,102,478 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION BY KEDAARA CAPITAL ALTERNATIVE INVESTMENT FUND – KEDAARA CAPITAL AIF 1 (“KARAKORAM LIMITED TOGETHER WITH KEDAARA CAPITAL ALTERNATIVE INVESTMENT FUND – KEDAARA CAPITAL AIF 1 REFERRED TO AS “INVESTOR SELLING SHAREHOLDERS”) (INVESTOR SELLING SHAREHOLDERS TOGETHER WITH THE PROMOTER SELLING SHAREHOLDER REFERRED TO AS THE “SELLING SHAREHOLDERS”). THIS OFFER INCLUDES A RESERVATION OF UP TO 150,000 EQUITY SHARES AGGREGATING UP TO ₹[●] MILLION (CONSTITUTING UP TO 0.15% OF THE POST-OFFER PAID-UP EQUITY SHARE CAPITAL) FOR PURCHASE BY ELIGIBLE EMPLOYEES (THE “EMPLOYEE RESERVATION PORTION”), THE OFFER LESS THE EMPLOYEE RESERVATION PORTION IS HEREINAFTER REFERRED TO AS THE “NET OFFER”. THE OFFER AND THE NET OFFER WOULD CONSTITUTE AT LEAST 35.00% AND 34.85%, RESPECTIVELY, OF OUR POST-OFFER PAID-UP EQUITY SHARE CAPITAL.

**QIB Portion: Not more than 50% of the Net Offer**

**Retail Portion: Not less than 35% of the Net Offer**

**Non-Institutional Portion: Not less than 15% of the Net Offer**

**Price Band: ₹ 522 to ₹ 531 per Equity Share of face value of ₹ 1 each.**

**A discount of ₹ 52 per Equity Share is being offered to Eligible Employees bidding in the Employee Reservation Portion.**

**The Floor Price is 522 times the face value of the Equity Shares and the Cap Price is 531 times the face value of the Equity Shares.**

**Bids can be made for a minimum of 28 Equity Shares and in multiples of 28 Equity Shares thereafter.**

**ASBA<sup>#</sup>**

**Simple, Safe, Smart way of Application!!!**

**# Applications supported by blocked amount (ASBA) is a better way of applying to issues by simply blocking the fund in the bank account, For further details, check section on ASBA below.**

**Mandatory in public issues. No cheque will be accepted.**

UPI-Now available in ASBA for Retail Individual Bidders (“RIBs”) applying through Registered Brokers, Syndicate, DPs and RTAs. RIBs also have the option to submit the application directly to the ASBA Bank (SCSBs) or to use the facility of linked online trading, demat and bank account.

**Bidders are required to ensure that the bank account used for bidding is linked to their PAN.**

ASBA is to be availed by all the investors except anchor investors. UPI may be availed by Retail Individual Bidders. For details on the ASBA and UPI process, please refer to the details given in ASBA form and abridged prospectus and also please refer to the section “Offer Procedure” on page 271 of the RHP. The process is also available on the website of Association of Investment Bankers of India (“AIBI”) and Stock Exchanges and in the General Information Document. ASBA bid-cum-application forms can be downloaded from the websites of BSE Limited (“BSE”) and National Stock Exchange of India Limited (“NSE”), and together with BSE, the “Stock Exchanges” and can be obtained from the list of banks that is displayed on the website of SEBI at www.sebi.gov.in. List of banks supporting UPI is also available on the website of www.sebi.gov.in. HDFC Bank Limited has been appointed as Sponsor Bank for the Offer, in accordance with the requirements of the UPI Circular. For Offer related grievance investors may contact: ICICI Securities Limited, Sameer Purohit/ Nidhi Wangnoo, Tel: +91 22 2288 2460, E-mail: vijaya\_ipo@icicisecurities.com; Edelweiss Financial Services Limited, Lokesh Shah/Nilesh Roy, Tel: +91 22 4009 4400, E-mail: vijayadiagnostic ipo@edelweissfin.com and Kotak Mahindra Capital Company Limited, Ganesh Rane, Tel: +91 22 4336 0000, E-mail: vijayadiagnostic.ipo@kotak.com. For UPI related queries, investors can contact NPCI at the toll free number: 18001201740 and Mail Id: ipo.upi@npci.org.in.

## Risks to Investors

- The 3 Book Running Lead Managers associated with the Offer have handled 44 public issues in the past three years, out of which 15 issues closed below the offer price on listing date.
- Average cost of acquisition of Equity Shares held by the Promoter Selling Shareholder is ₹ 0.34 per Equity Share and by the Investor Selling Shareholders is ₹ 99.49 per Equity share and Offer Price at upper end of the Price Band is ₹ 531 per Equity Share.
- Weighted Average Return on Net Worth for Fiscals 2021, 2020 & 2019 is 23.14%.
- The Price/Earnings ratio based on basic & diluted EPS for Fiscal 2021 for our Company at the higher end of the Price Band is 64.29, whereas the average industry peer group Price/Earnings ratio is 90.80.

## BASIS FOR THE OFFER PRICE

The Offer Price will be determined by our Company and the Selling Shareholders in consultation with the BRLMs, on the basis of assessment of market demand for the Equity Shares offered through the Book Building Process and on the basis of quantitative and qualitative factors as described below. The face value of the Equity Shares is ₹1 each and the Offer Price is 522 times the Floor Price and 531 times the Cap Price of the Price Band. Bidders should also see “Our Business”, “Risk Factors”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Financial Statements” on pages 110, 21, 225 and 161, respectively of the RHP, to have an informed view before making an investment decision.

**Qualitative Factors :** Some of the qualitative factors and our strengths which form the basis for computing the Offer Price are : • Largest and fastest growing diagnostic chain with dominant position in south India (*Source: CRISIL Report*), well positioned to leverage the high growth in Indian diagnostics industry; • Integrated diagnostics provider that offers one-stop solution at affordable price with focus on superior quality standards; • High brand recall driving high individual consumer business share and customer stickiness; • Strong technical capabilities, quality infrastructure and state-of-the-art medical technology with strong IT infrastructure; and • Dedicated management team with significant industry experience For details, see “Our Business – Our Competitive Strengths” on page 111 of the RHP.

**Quantitative Factors :** Some of the information presented below relating to our Company is derived from the Restated Financial Information. For details, see “Financial Statements” on page 161 of the RHP. Some of the quantitative factors which may form the basis for computing the Offer Price are as follows:

**A. Basic and Diluted Earnings Per Share (“EPS”), as adjusted for changes in capital:**

As derived from the Restated Financial Information

Financial Year/ period ended	Basic EPS <sup>A</sup> (Face value of ₹1 each) (in ₹)	Diluted EPS <sup>A</sup> (Face value of ₹1 each) (in ₹)	Weight
Year ended March 31, 2021	8.26	8.26	3
Year ended March 31, 2020	6.13	6.13	2
Year ended March 31, 2019	4.50	4.50	1
<b>Weighted average</b>	<b>6.92</b>	<b>6.92</b>	
Three month period ended June 30, 2021 (not annualised)	3.23	3.23	
Three month period ended June 30, 2020 (not annualised)	0.19	0.19	

Notes: The ratios have been computed as under:

1. Basic and diluted EPS: Restated profit for the year attributable to equity shareholders of the Company divided by total weighted average number of equity shares outstanding during the period. Basic and diluted EPS are computed in accordance with Ind AS 33 - Earnings per share;

2. Weighted average = Aggregate of year-wise weighted EPS divided by the aggregate of weights i.e. (EPS x Weight) for each year/Total of weights

<sup>A</sup> Our Company has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the equity shares of face value of ₹10 each to Equity Shares of face value of ₹1 each. Further, subsequent to March 31, 2021, pursuant to a Board resolution dated May 26, 2021 and Shareholders resolution dated May 26, 2021, our Company has capitalised the securities premium account to issue bonus Equity Shares in the ratio of 5 Equity Shares for every 4 Equity Shares held. Basic and diluted EPS are considered

post sub-division and bonus issue.

**B. Price/Earning (“P/E”) ratio in relation to the Price Band of ₹522 to ₹531 per Equity Share:**

Particulars	P/E at the lower end of the Price Band (no. of times)	P/E at the higher end of the Price Band (no. of times)
Based on basic EPS for year ended March 31, 2021	63.20	64.29
Based on diluted EPS for year ended March 31, 2021	63.20	64.29

**Industry Peer Group P/E ratio**

Particulars	P/E Ratio
Highest	107.3
Lowest	74.4
<b>Average</b>	<b>90.8</b>

**C. Return on Net Worth (“RoNW”)**

As derived from the Restated Financial Information:

Financial Year ended	RoNW (%)	Weight
March 31, 2021	23.64%	3
March 31, 2020	22.80%	2
March 31, 2019	22.35%	1
Weighted Average	23.14%	
June 30, 2021 (not annualised)	8.48%	
June 30, 2020 (not annualised)	0.65%	

Notes: The ratio has been computed as under:

1. Return on net worth %: Profit after tax for the year attributable to equity shareholders of the Company divided by net worth as attributable to equity shareholders of the Company at the end of the year\*100.

2. Net worth = net worth means the aggregate value of paid-up equity share capital and other equity created out of the profits, securities premium account and debit or credit balance of profit and loss account, after deducting the aggregate value of the accumulated losses, deferred expenditure and miscellaneous expenditure not written off, derived from the Restated Financial Information, but does not include reserves created out of revaluation of assets, write-back of depreciation and amalgamation.

3. The Weighted Average Return on Net Worth is a product of Return on Net Worth and respective assigned weight, dividing the resultant by total aggregate weight. i.e. (RoNW x Weight) for each year/Total of weights.

As the Offer consists only of an offer for sale by the Selling Shareholders, there will be no change in the Net Worth post completion of the Offer.

**D. Net Asset Value (“NAV”) per Equity Share**

As at	Restated Financial Information (₹)
June 30, 2021	38.53
Offer Price	[●]

Notes: Net assets value per share (in ₹): Net asset value per share is calculated by dividing net worth by number of equity shares outstanding at the end of the year.

As the Offer consists only of an offer for sale by the Selling Shareholders, there will be no change in the NAV post completion of the Offer.

**E. Comparison with Listed Industry Peers**

Name of the company	Face value per equity share (₹)	P/E	Net Profit (₹ in million)	EPS (Basic) (₹)	EPS (Diluted) (₹)	Net worth (₹ in million)	RoNW (%)	Net Asset Value/ Equity Share (₹)	Closing Share Price as on August 11, 2021 (₹ per equity share)
Vijaya Diagnostic Centre Limited	1	NA	849.11	8.26	8.26	3,592.32	23.64%	35.23	NA
Dr. Lal Path Labs Limited	10	107.3	2,916	35.33	35.25	12,450	23.42%	149.38	3,791.15
Metropolis Healthcare Limited	2	74.4	1,831	35.97	35.79	7,066	25.91%	138.23	2,675.65

Source: All the financial information for listed industry peer mentioned above is on a consolidated basis and is sourced from the annual audited financial results of the company for the year ended March 31, 2021

Source for our Company: Based on the Restated Financial Information for the year ended March 31, 2021

Basic and diluted EPS are computed in accordance with Ind AS 33 - Earnings per share.

<sup>A</sup> Our Company has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the equity shares of face value of ₹10 each to Equity Shares of face value of ₹1 each. Further, subsequent to March 31, 2021, pursuant to a Board resolution dated May 26, 2021 and Shareholders resolution dated May 26, 2021, our Company has capitalised the securities premium account to issue bonus Equity Shares in the ratio of 5 Equity Shares for every 4 Equity Shares held. Basic and diluted EPS are considered post sub-division and bonus issue.

Notes: (1) P/E Ratio has been computed based on the closing market price of equity shares on BSE on August 11, 2021, divided by the Basic EPS. (2) Net Profit is the Profit for the year attributable to equity shareholders of the Company. (3) Return on net worth %: Profit for the year attributable to equity shareholders of the Company divided by net worth as attributable to equity shareholders of the Company at the end of the year. (4) Net worth has been computed as sum of paid-up share capital and other equity. (5) NAV is computed as the closing net worth divided by the closing outstanding number of equity shares. Our Company has, pursuant to a Board resolution dated March 22, 2021 and Shareholders resolution dated March 22, 2021, sub-divided the equity shares of face value of ₹10 each to Equity Shares of face value of ₹1 each. Further, subsequent to March 31, 2021, pursuant to a Board resolution dated May 26, 2021 and Shareholders resolution dated May 26, 2021, bonus share has been issued in the ratio of 5 equity shares for every 4 equity shares. Net asset value per share is considered post sub-division and bonus issue.

**F. The Offer Price is [●] times of the face value of the Equity Shares**

The Offer Price of ₹[●] has been determined by our Company and the Selling Shareholders in consultation with the BRLMs, on the basis of market demand from investors for Equity Shares through the Book Building Process and is justified in view of the above qualitative and quantitative parameters.

Investors should read the above mentioned information along with “Risk Factors”, “Our Business”, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Financial Statements” on pages 21, 110, 225 and 161, respectively of the RHP, to have a more informed view.

The trading price of the Equity Shares could decline due to the factors mentioned in the “Risk Factors” on page 21 of the RHP and you may lose all or part of your investment.

## BID/ OFFER SCHEDULE

**OPENS ON: WEDNESDAY, SEPTEMBER 1, 2021<sup>(1)</sup> | CLOSES ON: FRIDAY, SEPTEMBER 3, 2021<sup>#</sup>**

<sup>(1)</sup> Our Company and the Selling Shareholders in consultation with the BRLMs, may consider participation by Anchor Investors in accordance with the SEBI ICDR Regulations. The Anchor Investor Bid/ Offer Period shall be one Working Day prior to the Bid/ Offer Opening Date.

<sup>#</sup>UPI Mandate end time shall be 12 noon on September 6, 2021.

In case of any revision in the Price Band, the Bid/ Offer Period will be extended by at least three additional Working Days after such revision in the Price Band, subject to the Bid/ Offer Period not exceeding 10 Working Days. In cases of force majeure, strike or similar circumstances, our Company may, for reasons to be recorded in writing, extend the Bid/ Offer Period for a minimum of three Working Days, subject to the Bid/ Offer Period not exceeding 10 Working Days. Any revision in the Price Band and the revised Bid/ Offer Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges, by issuing a press release, and also by indicating the change on the respective websites of the BRLMs and at the terminals of the Syndicate Members and by intimation to Designated Intermediaries and the Sponsor Bank, as applicable.

The Offer is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended (“SCRR”) read with Regulation 31 of the SEBI ICDR Regulations and in compliance with Regulation 6(1) of the SEBI ICDR Regulations wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (the “QIB Portion”), provided that our Company and the Selling Shareholders in consultation with the BRLMs may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis. One-third of the Anchor Investor Portion shall be reserved for domestic Mutual Funds, subject to valid Bids being received from the domestic Mutual Funds at or above the Anchor Investor Allocation Price. 5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. However, if the aggregate demand from Mutual Funds is less than 5% of the QIB Portion, the balance Equity Shares available for allocation in the Mutual Fund Portion will be added to the remaining QIB Portion for proportionate allocation to QIBs. Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Offer shall be available for allocation to RIBs in accordance with the SEBI ICDR Regulations, subject to valid Bids being received from them at or above the Offer Price. Further, Equity Shares will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids received from them at or above the Offer Price. All potential Bidders (except Anchor Investors) are required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective bank account (including UPI ID for RIBs using UPI Mechanism), in which the corresponding Bid Amounts will be blocked by the SCSBs or the Sponsor Bank, as applicable. Anchor Investors are not permitted to participate in the Offer through the ASBA process. For details, see “Offer Procedure” on page 271 of the RHP.

Bidders/Applicants should note that on the basis of the PAN, DP ID and Client ID and UPI ID (for RIBs bidding through UPI Mechanism) as provided in the Bid cum Application Form, the Bidder/Applicant may be deemed to have authorised the Depositories to provide to the Registrar to the Offer, any requested Demographic Details of the Bidder/Applicant as available on the records of the depositories. These Demographic Details may be used, among other things, for unblocking of ASBA Account or for other correspondence(s) related to the Offer. Bidders/Applicants are advised to update any changes to their Demographic Details as available in the records of the Depository Participant to ensure accuracy of records. Any delay resulting from failure to update the Demographic Details would be at the Bidders/Applicants’ sole risk.

**Contents of the Memorandum of Association of the Company as regards its objects:** For information on the main objects of the Company, please see the section entitled “History and Certain Corporate Matters” on page 130 of the RHP and Clause III of the Memorandum of Association of the Company. The Memorandum of Association of the Company is a material document for inspection in relation to the Offer. For further details, please see the section entitled “Material Contracts and

Documents for Inspection” on page 290 of the RHP.

**Liability of the members of the Company:** Limited by shares

**Amount of share capital of the Company and Capital structure:** The authorised, issued, subscribed and paid-up share capital of the Company as on the date of the RHP is as follows: The authorised share capital of the Company is ₹ 120,500,000 divided into 120,500,000 Equity Shares of ₹1 each. The issued, subscribed and paid-up share capital of the Company is ₹ 101,965,926 divided into 101,965,926 Equity Shares of ₹1 each. For details, please see the section entitled “Capital Structure” beginning on page 55 of the RHP.

**Names of signatories to the Memorandum of Association of the Company and the number of Equity Shares subscribed by them:** The names of the signatories of the Memorandum of Association of the Company are Dr. S. Surendranath Reddy, S. Geeta Reddy, Sunil Chandra Kondapally, B. Vishnu Priya and Sura Suprita Reddy. For details of share capital history, please see the section entitled “Capital Structure” beginning on page 55 of the RHP.

**Listing:** The Equity Shares offered through the Red Herring Prospectus are proposed to be listed on the Stock Exchanges. Our Company has received ‘in-principle’ approval from BSE and NSE for the listing of the Equity Shares pursuant to letters dated July 5, 2021 and June 30, 2021, respectively. For the purposes of the Offer, the Designated Stock Exchange shall be NSE. A signed copy of the Red Herring Prospectus and the Prospectus shall be delivered for filing with the RoC in accordance with Section 26(4) of the Companies Act. For details of the material contracts and documents available for inspection from the date of the Red Herring Prospectus up to the Bid/ Offer Closing Date, see “Material Contracts and Documents for Inspection” on page 290 of the RHP.

**Disclaimer Clause of the SEBI:** The Securities and Exchange Board of India (“SEBI”) only gives its observations on the offer documents and this does not constitute approval of either the Offer or the specified securities or the offer document. The investors are advised to refer to page 254 of the RHP for the full text of the Disclaimer Clause of SEBI.

**Disclaimer Clause of NSE (Designated Stock Exchange) :** It is to be distinctly understood that the permission given by NSE should not in any way be deemed or construed that the RHP has been cleared or approved by NSE nor does it certify the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to page 256 of the RHP for the full text of the Disclaimer Clause of NSE.

**Disclaimer Clause of BSE :** It is to be distinctly understood that the permission given by BSE should not in any way be deemed or construed that the RHP has been cleared or approved by BSE nor does it certify the correctness or completeness of any of the contents of the RHP. The investors are advised to refer to page 256 of the RHP for the full text of the Disclaimer Clause of BSE.

**General Risks:** Investments in equity and equity-related securities involve a degree of risk and investors should not invest any funds in the Offer unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in the Offer. For taking an investment decision, investors must rely on their own examination of our Company and the Offer, including the risks involved. The Equity Shares in the Offer have not been recommended or approved by the Securities and Exchange Board of India (“SEBI”), nor does SEBI guarantee the accuracy or adequacy of the contents of the Red Herring Prospectus. Specific attention of the prospective investors is invited to “Risk Factors” on page 21 of the RHP.

BOOK RUNNING LEAD MANAGERS			REGISTRAR TO THE OFFER	COMPANY SECRETARY AND COMPLIANCE OFFICER
				<b>V. Sri Lakshmi</b> 3-6-16 & 17, Street No. 19, Himayatnagar, Hyderabad, Telangana, India. Tel: 40-23420411 E-mail: ir@vijayadiagnostic.in
<b>ICICI Securities Limited</b> ICICI Centre, H. T. Parekh Marg, Churchgate, Mumbai - 400 020, Maharashtra, India Tel: +91 22 2288 2460 E-mail: vijaya.ipo@icicisecurities.com Investor grievance e-mail: customercare@icicisecurities.com Website: www.icicisecurities.com Contact Person: Sameer Purohit/ Nidhi Wangnoo SEBI Registration No.: INM000011179	<b>Edelweiss Financial Services Limited</b> 6 <sup>th</sup> Floor, Edelweiss House, Off C.S.T. Road, Kalina, Mumbai - 400 098, Maharashtra, India Tel: +91 22 4009 4400 E-mail: vijayadiagnostic.ipo@edelweissfin.com Website: www.edelweissfin.com Investor Grievance email: customerservice.mb@edelweissfin.com Contact person: Lokesh Shah/Nilesh Roy SEBI Registration No.: INM0000010650	<b>Kotak Mahindra Capital Company Limited</b> 1 <sup>st</sup> Floor, 27 BKC, Plot No. 27, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051, Maharashtra, India Tel: +91 22 4336 0000 E-mail: vijayadiagnostic.ipo@kotak.com Investor grievance e-mail: kmcdressal@kotak.com Website: https://investmentbank.kotak.com Contact Person: Ganesh Rane SEBI Registration No.: INM000008704	<b>KFin Technologies Private Limited</b> Selenium, Tower B, Plot No. 31 and 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareedi - 500 032, Telangana, India Tel: +91 40 6716 2222/ 1800 309 4001 E-mail: vijaya.ipo@kfintech.com Investor grievance e-mail: einward.ris@kfintech.com Website: www.kfintech.com Contact Person: M Murali Krishna SEBI Registration No.: INR000000221	

**AVAILABILITY OF THE RHP:** Investors are advised to refer to the RHP and the “Risk Factors”, contained therein before applying in the Offer. Full copy of the RHP is available on website of SEBI at www.sebi.gov.in, website of the BRLMs, i.e. ICICI Securities Limited, Edelweiss Financial Services Limited and Kotak Mahindra Capital Company Limited at www.icicisecurities.com, www.edelweissfin.com and https://investmentbank.kotak.com, respectively and on the websites of BSE and NSE at www.bseindia.com and www.nseindia.com, respectively.

**AVAILABILITY OF BID CUM APPLICATION FORMS:** Bid cum Application Forms can be obtained from the Registered Office of Vijaya Diagnostic Centre Limited, Tel: +91 40 2342 0411 **BRLMs : ICICI Securities Limited, Tel: +91 22 2288 2460, Edelweiss Financial Services Limited, Tel: +91 22 4009 4400 and Kotak Mahindra Capital Company Limited, Tel: +91 22 4336 0000 and Syndicate Members : Kotak Securities Limited, Tel: +91 22 6218 5470 and Edelweiss Securities Limited, Tel: +91 22 4063 5569**, at the select locations of the Sub-syndicate Members (as given below), SCSBs, Registered Brokers, RTAs and CDPs participating in the Offer. ASBA Forms will also be available on the websites of BSE and NSE and the Designated Branches of SCSBs, the list of which is available at websites of the Stock Exchanges and SEBI.

**Sub-Syndicate Members:** Almondz Global Securities Ltd, Anand Rathi Share & Stock Brokers Ltd, Axis Capital Ltd, Centrum Wealth Management Ltd, Choice Equity Broking Private Limited, DALAL & BROADACHA STOCK BROKING LTD., DB(International) Stock Brokers Ltd, EDELWEISS BROKING LTD., Eureka Stock & Share Broking Services Ltd, Finwizard Technology Pvt Limited, HDFC SECURITIES LTD., ICICI Securities Limited, IDBI Capital Markets & Securities Limited, IIFL SECURITIES LTD., J M Financial Services Ltd, Jobanputra Fiscal Services Pvt Ltd, KJMC Capital Market Services Limited, LKP Securities Ltd, Inventure Growth & Securities Ltd, Motilal Oswal Securities Ltd, Nirmal Bang Securities Pvt. Ltd., Prabhudas Liladhar Pvt Ltd, Pravin Ratilal Share and Stock Brokers Ltd, RR Equity Brokers Pvt Ltd, SBicap Securities Limited, Sharekhan Ltd, SMC Global Securities Ltd, Systematix Shares and Stocks (India) Limited, Trade Bulls Securities (P) Ltd and YES Securities (India) Limited

**Escrow Collection Bank/ Refund Bank/ Public Offer Bank/ Sponsor Bank:** HDFC Bank Limited

UPI: Retail Individual Investors can also Bid through UPI mechanism.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the RHP.

Place: Hyderabad  
Date: August 25, 2021

For Vijaya Diagnostic Centre Limited  
On behalf of the Board of Directors  
Sd/-  
Company Secretary and Compliance Officer

**Vijaya Diagnostic Centre Limited** is proposing, and subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offering of its Equity Shares and has filed the RHP with RoC. The RHP shall be available on the website of SEBI at www.sebi.gov.in, websites of the Stock Exchanges i.e. BSE and NSE at www.bseindia.com and www.nseindia.com, respectively, and is available on the websites of the BRLMs i.e. ICICI Securities Limited, Edelweiss Financial Services Limited and Kotak Mahindra Capital Company Limited at www.icicisecurities.com, www.edelweissfin.com and https://investmentbank.kotak.com, respectively. Bidders should note that investment in equity shares involves a high degree of risk and for details relating to the same, please see the section entitled “Risk Factors” on page 21 of the RHP. Potential Bidders should not rely on the DRHP filed with SEBI for making any investment decision.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) under Section 4(a) of the U.S. Securities Act, and (ii) outside the United States in offshore transactions as defined in and in compliance with Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of Equity Shares in the United States.